[ 177 Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies
Journal of Nuclear Medicine · 2026
DOI: 10.2967/jnumed.125.271705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Amanda Gustafsson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; amanda.gustafsson@igp.uu.se. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Lutetium, Hyaluronan Receptors, Radioisotopes. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive, with a 5-y survival rate of less than 5% for patients with advanced disease. CD44v6 is frequently overexpressed in the malignancy, representing a promising therapeutic target. Here, we evaluated the efficacy of [177Lu]Lu-AKIR001, a CD44v6-targeting radiopharmaceutical, alone and combined with chemotherapy for the treatment of PDAC.
Methods
CD44v6 expression, radioligand binding, and chemotherapy sensitivity were assessed in PDAC cell lines. Mice bearing PDAC xenografts received [177Lu]Lu-AKIR001, chemotherapy, or a combination of the two modalities. Toxicity was determined by body weight monitoring and hematologic and organ analyses.
Results
Three of the 4 cell lines expressed CD44v6. In vivo, tumor uptake exceeded 100 %IA/g. Tumor growth inhibition was activity-dependent, with complete remissions detected after the administration of 12 MBq of [177Lu]Lu-AKIR001 (40%) and 4 MBq of [177Lu]Lu-AKIR001 combined with paclitaxel (14%). Conclusion: [177Lu]Lu-AKIR001 demonstrated activity-dependent therapeutic potential in mice bearing PDAC xenografts. Combination therapy with paclitaxel indicated potential synergistic benefit, but further investigation and optimization are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; amanda.gustafsson@igp.uu.se.
- Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Zitieren
APA
Gustafsson, A., Svedberg, H., Rinne, S. S., Bertilsson, F., Selvaraju, R. K., Lundgren Mortensen, A. C., Lindskog, C., & Nestor, M. (2026). [ 177 Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271705
Vancouver
Gustafsson A, Svedberg H, Rinne SS, Bertilsson F, Selvaraju RK, Lundgren Mortensen AC, et al. [ 177 Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271705
BibTeX
@article{Gustafsson2026,
author = {Gustafsson, Amanda and Svedberg, Hedvig and Rinne, Sara S and Bertilsson, Filippa and Selvaraju, Ram Kumar and Lundgren Mortensen, Anja C and Lindskog, Cecilia and Nestor, Marika},
title = {[ 177 Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.271705}
}
EUVIMED